A Study of the Dose Proportionality of Extended Release Paliperidone
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to evaluate the dose proportionality of 1.5- and 3 mg tablets
of paliperidone ER, to document the pharmacokinetics of a 1.5 mg dose of paliperidone ER, and
to assess the safety and tolerability of the 1.5- and 3 mg tablets in healthy men.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.